Related Experiment Video

Updated: Mar 30, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K

G1896A Precore Mutation and Association With HBeAg Status, Genotype and Clinical Status in Patients With Chronic

Jeyanthi Suppiah1, Rozainanee Mohd Zain1, Norazlah Bahari2

  • 1Virology Unit, Institute for Medical Research, Kuala Lumpur, Malaysia.

Hepatitis Monthly
|November 21, 2015
PubMed
Abstract

Insights

The G1896A precore stop codon mutation is found in 25.8% of Malaysian chronic hepatitis B patients. This mutation is significantly associated with hepatitis B virus genotype B and liver cirrhosis.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • The precore stop codon (G1896A) mutation is common in chronic hepatitis B.
  • This mutation has been infrequently reported in Malaysia previously.

Purpose of the Study:

  • To investigate the prevalence of the G1896A mutation in the Malaysian population.
  • To determine its association with hepatitis B e antigen (HBeAg) status, clinical stage, HBV genotype, and e-seroconversion rate.

Main Methods:

  • Serum samples from 93 hepatitis B carriers were analyzed.
  • Whole genome sequencing of HBV was performed using polymerase chain reaction.
  • Precore and basal core promoter regions were examined for mutations.

Main Results:

  • The G1896A mutation was identified in 25.8% of isolates.
  • G1896A showed a high prevalence among HBV genotype B.
  • The mutation was associated with asymptomatic chronic hepatitis B, liver cirrhosis, and notably, fulminant hepatitis and hepatocellular carcinoma (HCC).

Conclusions:

  • An intermediate prevalence of the G1896A mutation was observed in Malaysian hepatitis B carriers.
  • The G1896A mutation is significantly associated with HBV genotype B and patients presenting with chronic hepatitis B and liver cirrhosis.
Keywords:
G1896AGenotypeHepatitis BLiver CirrhosisPrecore

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
743
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
24
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
345